1. Abbvie (2022) U.S. FDA approves RINBOQ® (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis. https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm. Accessed 24 Aug 2022
2. Akhavan A, Rudikoff D (2008) Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg 27:151–155. https://doi.org/10.1016/j.sder.2008.04.004
3. Almiral (2022) 16 weeks data for lebrikizumab advocate 1 and 2 phase 3 studies has been announced today at the American academy of dermatology (AAD) annual meeting. https://www.almirall.com/documents/portlet_file_entry/4257831/26032022_LEBRI+Phase+III+AAD_ENG+nv+with+PR.pdf/72121fc5-541f-dc0d-e721-64618026e340. Accessed 15 Aug 2022
4. Almiral (2022) 16 Weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies has been announced today at the American academy of dermatology (AAD) Annual Meeting. https://www.almirall.com/documents/portlet_file_entry/4257831/26032022_LEBRI+Phase+III+AAD_ENG+nv+with+PR.pdf/72121fc5-541f-dc0d-e721-64618026e340. Accessed 15 Aug 2022
5. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, van Wijk F, de Bruin-Weller MS, Drylewicz J, Thijs JL (2021) Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. J Allergy Clin Immunol 147:189–198. https://doi.org/10.1016/j.jaci.2020.04.062